ATE99358T1 - Alpha-1-antitrypsinmutante und dafuer kodierende dns und herstellung derselben, und solche mutante verwendende therapeutische zusammensetzungen und ihre herstellung. - Google Patents

Alpha-1-antitrypsinmutante und dafuer kodierende dns und herstellung derselben, und solche mutante verwendende therapeutische zusammensetzungen und ihre herstellung.

Info

Publication number
ATE99358T1
ATE99358T1 AT85301790T AT85301790T ATE99358T1 AT E99358 T1 ATE99358 T1 AT E99358T1 AT 85301790 T AT85301790 T AT 85301790T AT 85301790 T AT85301790 T AT 85301790T AT E99358 T1 ATE99358 T1 AT E99358T1
Authority
AT
Austria
Prior art keywords
mutants
production
alpha
dna encoding
therapeutic compositions
Prior art date
Application number
AT85301790T
Other languages
English (en)
Inventor
Margaret Y Insley
Glenn Kawasaki
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Application granted granted Critical
Publication of ATE99358T1 publication Critical patent/ATE99358T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
AT85301790T 1984-03-14 1985-03-14 Alpha-1-antitrypsinmutante und dafuer kodierende dns und herstellung derselben, und solche mutante verwendende therapeutische zusammensetzungen und ihre herstellung. ATE99358T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58941084A 1984-03-14 1984-03-14
US06/709,382 US4711848A (en) 1984-03-14 1985-03-07 Site specific mutagenesis in alpha-1-antitrypsin
EP85301790A EP0155188B1 (de) 1984-03-14 1985-03-14 Alpha-1-Antitrypsinmutante und dafür kodierende DNS und Herstellung derselben, und solche Mutante verwendende therapeutische Zusammensetzungen und ihre Herstellung

Publications (1)

Publication Number Publication Date
ATE99358T1 true ATE99358T1 (de) 1994-01-15

Family

ID=27080550

Family Applications (1)

Application Number Title Priority Date Filing Date
AT85301790T ATE99358T1 (de) 1984-03-14 1985-03-14 Alpha-1-antitrypsinmutante und dafuer kodierende dns und herstellung derselben, und solche mutante verwendende therapeutische zusammensetzungen und ihre herstellung.

Country Status (7)

Country Link
US (1) US4711848A (de)
EP (2) EP0566158A1 (de)
JP (3) JP2539781B2 (de)
AT (1) ATE99358T1 (de)
AU (1) AU593766B2 (de)
CA (1) CA1341219C (de)
DE (1) DE3587703D1 (de)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA8410063B (en) * 1984-01-30 1985-10-30 Smith Kline Rit Expression of human alpha-1-antitrypsin in yeast
DE3585969D1 (de) * 1984-06-14 1992-06-11 Chiron Corp Protease-inhibitoren des alpha-1-antitrypsin typs mit modifizierter aktiever stelle und deren herstellung.
US4732973A (en) * 1984-06-14 1988-03-22 Chiron Corporation Active site modified protease α-1-antitrypsin inhibitors
EP0169114B1 (de) * 1984-06-19 1991-01-16 Transgene S.A. Derivate des menschlichen alpha-1-Antitrypins und Verfahren zu deren Herstellung
US5422090A (en) * 1984-08-13 1995-06-06 Biotechnology Australia, Pty., Ltd. Human PAI-2
CA1299120C (en) * 1984-10-22 1992-04-21 Glenn Kawasaki Stable dna constructs for expression of alpha-1-antitrypsin
US6291662B1 (en) 1984-12-05 2001-09-18 Amgen Inc. Recombinant methods for production of serine protease inhibitors and DNA sequences
US5871956A (en) * 1984-12-06 1999-02-16 Amgen Inc. Recombinant methods for production of serine inhibitors and DNA sequences useful for same
HU204563B (en) * 1984-12-06 1992-01-28 Synergen Biolog Inc Process for producing recombinant serine-protease inhibitors and dns sequencyes for them
US5900400A (en) * 1984-12-06 1999-05-04 Amgen Inc. Serine protease inhibitor analogs
DE3587526T3 (de) * 1984-12-06 2002-08-08 Amgen Inc.(N.D.Ges D. Staates Delaware), Thousand Oaks Serinproteaseinhibitoren und isolierungsverfahren dazu.
US6132990A (en) * 1984-12-06 2000-10-17 Amgen Boulder Inc. Recombinant methods for production of serine protease inhibitors and DNA sequences useful for same
ES8706823A1 (es) * 1985-03-28 1987-06-16 Cetus Corp Un procedimiento para detectar la presencia o ausencia de al menos una secuencia especifica de acidos nucleicos en una muestra
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
NZ218148A (en) * 1985-11-08 1989-06-28 Smithkline Beckman Corp E.coli expression vector coding for alpha-1-antitrypsin
FR2599752B1 (fr) * 1986-06-10 1989-11-03 Transgene Sa Variants de l'alpha1- antitrypsine utiles notamment comme inhibiteurs de la kallikreine
EP0253193B1 (de) * 1986-07-08 1992-10-28 Abbott Laboratories Verfahren für die Mutagenese durch eine oligonukleotidgeleitete Reparatur eines Strangbruchs
JP2656944B2 (ja) * 1987-04-30 1997-09-24 クーパー ラボラトリーズ タンパク質性治療剤のエアロゾール化
NZ226543A (en) * 1987-10-22 1992-02-25 Merck & Co Inc Recombinant mutant acidic fibroblast growth factor
US5648254A (en) * 1988-01-15 1997-07-15 Zymogenetics, Inc. Co-expression in eukaryotic cells
US5698418A (en) * 1988-02-17 1997-12-16 Pharmacia & Upjohn Company Fermentation media and methods for controlling norleucine in polypeptides
US5180667A (en) * 1988-03-07 1993-01-19 Ciba-Geigy Corporation Genes encoding eglin C mutants
DE58907373D1 (de) * 1988-03-07 1994-05-11 Ciba Geigy Modifizierte Proteine.
DE3901917A1 (de) * 1989-01-24 1990-07-26 Behringwerke Ag Mutanten von humanem antithrombin iii
ES2066033T3 (es) * 1989-05-13 1995-03-01 Bayer Ag Inhibidores de las proteinasas, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
US5518907A (en) * 1989-06-07 1996-05-21 Center For Innovative Technology Cloning and expression in Escherichia coli of the Alcaligenes eutrophus H16 poly-beta-hydroxybutyrate biosynthetic pathway
US5334520A (en) * 1990-05-25 1994-08-02 Center For Innovative Technology Production of poly-beta-hydroxybutyrate in transformed escherichia coli
US5358932A (en) * 1989-12-29 1994-10-25 Zymogenetics, Inc. Hybrid protein C
JP3270462B2 (ja) * 1989-12-29 2002-04-02 ザイモジェネティクス，インコーポレイティド ハイブリッドプロテインｃ
US6869925B1 (en) * 1992-09-09 2005-03-22 Amgen Inc. Inhibition of retrovirus infection
JP3929484B2 (ja) * 1993-09-14 2007-06-13 ジェネンテック・インコーポレーテッド エコチンおよびその同族体を含む医薬的組成物
US6017880A (en) * 1994-03-09 2000-01-25 Amgen Inc. Inhibition of retrovirus infection
AU3479495A (en) * 1994-09-30 1996-04-26 Ppl Therapeutics (Scotland) Ltd Alpha-1-antitrypsin and antithrombine-iii variants
US6315995B1 (en) * 1996-09-27 2001-11-13 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
US6316403B1 (en) 1996-09-27 2001-11-13 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
US8128963B2 (en) * 1996-09-27 2012-03-06 The Trustees Of Columbia University In The City Of New York Methods for treating ischemic disorders using carbon monoxide
GB2318732A (en) 1996-11-01 1998-05-06 Johnson & Johnson Medical Wound healing compositions containing alpha-1-antitrypsin
CA2283789C (en) 1997-03-12 2005-07-05 Applied Biosystems, Llc Dna polymerases having improved labeled nucleotide incorporation properties
AU3864000A (en) * 1999-03-05 2000-09-21 Trustees Of University Technology Corporation, The Inhibitors of serine protease activity, methods and compositions for treatment of herpes viruses
AU3731400A (en) * 1999-03-05 2000-09-21 Trustees Of University Technology Corporation, The Methods and compositions useful in inhibiting apoptosis
US6489308B1 (en) 1999-03-05 2002-12-03 Trustees Of University Of Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of nitric-oxide-induced clinical conditions
US6849605B1 (en) * 1999-03-05 2005-02-01 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
US20050250688A1 (en) * 1999-04-01 2005-11-10 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
AU2002258997A1 (en) * 2001-04-24 2002-11-05 Li-Cor, Inc. Polymerases with charge-switch activity and methods of generating such polymerases
US20050042629A1 (en) 2002-09-13 2005-02-24 Applera Corporation Thermus scotoductus nucleic acid polymerases
AU2002346498A1 (en) 2001-11-30 2003-06-17 Applera Corporation Thermus brockianus nucleic acid polymerases
US20040220242A1 (en) * 2003-05-02 2004-11-04 Leland Shapiro Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide induced clinical conditions
CA2534352A1 (en) * 2003-08-08 2005-02-17 Arriva Pharmaceuticals, Inc. Methods of protein production in yeast
PL2520654T3 (pl) 2003-08-26 2017-08-31 The Regents Of The University Of Colorado, A Body Corporate Inhibitory aktywności proteazy serynowej i ich zastosowanie w sposobach i kompozycjach do leczenia zakażeń bakteryjnych
JP2007511539A (ja) * 2003-11-14 2007-05-10 バクスター・インターナショナル・インコーポレイテッド α１−抗トリプシン組成物およびこのような組成物を用いた処置方法
US20070105768A1 (en) * 2004-11-10 2007-05-10 Rajiv Nayar Dry recombinant human alpha 1-antitrypsin formulation
GB2446550B (en) * 2005-11-28 2010-12-08 Proteomtech Inc Methods for production of recombinant alpha1-antitrypsin
MX2009006369A (es) 2006-12-15 2010-02-24 Lifebond Ltd Apositos y selladores hemostaticos de gelatina-transglutaminasa.
US8133484B2 (en) 2006-12-15 2012-03-13 Lifebond Ltd Hemostatic materials and dressing
KR100992526B1 (ko) * 2007-11-21 2010-11-05 한국과학기술연구원 이황화결합을 이용한 내열성의 알파-1-안티트립신 뮤테인및 그의 제조방법
EP2303344A2 (de) * 2008-06-18 2011-04-06 Lifebond Ltd Verfahren und vorrichtungen zur verwendung mit dichtungsmitteln
CN104031393B (zh) 2008-06-18 2017-08-01 生命连结有限公司 改进的交联组合物
WO2009153751A2 (en) * 2008-06-18 2009-12-23 Lifebond Ltd A method for enzymatic cross-linking of a protein
PT2496246T (pt) 2009-11-03 2018-07-31 Grifols Therapeutics Llc Composição, método e kit para o inibidor da alfa-1 protease
RU2540480C2 (ru) 2009-11-24 2015-02-10 Грифольс Терапьютикс Инк. Способы, композиции и наборы для лиофилизации
JP5796860B2 (ja) 2009-12-22 2015-10-21 ライフボンド リミテッドＬｉｆｅｂｏｎｄ Ｌｔｄ 架橋マトリックスの特性を調節するための酵素的架橋剤の改変
EP2600910B1 (de) 2010-08-05 2016-01-20 Lifebond Ltd Wundverbände mit einer trockenzusammung und haftstoffe
US20140093556A1 (en) 2011-01-28 2014-04-03 Sanofi Pasteur Sa Immunological Compositions Against HIV
KR20200044138A (ko) 2011-06-24 2020-04-28 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 알파-1 안티트립신 융합 분자용 조성물, 방법 및 용도
EP2592421B1 (de) 2011-11-14 2017-08-30 Universitätsklinikum Jena Diagnose von blutvergiftung und des systemischen entzündungsreaktionssyndroms
MX351189B (es) 2011-12-30 2017-10-04 Grifols Sa Inhibidor de alfa1-proteinasa para demorar el comienzo o progresión de exacerbaciones pulmonares.
JP2015504675A (ja) 2012-01-10 2015-02-16 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ アルファ−１アンチトリプシン融合分子の組成物、方法、及び使用
ES2799153T3 (es) 2013-03-29 2020-12-15 Univ Colorado Regents Alfa 1 antitripsina para uso en la preparación de un sujeto para trasplante
GB201322091D0 (en) 2013-12-13 2014-01-29 Cambridge Entpr Ltd Modified serpins for the treatment of bleeding disorders
US20190008935A1 (en) 2015-12-31 2019-01-10 The Regents Of The University Of Colorado, A Bodo Corporate Methods and uses for alpha-1 antitrypsin or recombinant forms thereof, on steroid-refractory graft versus host disease involving gastrointestinal complications
EP3600345A4 (de) * 2017-03-29 2021-01-06 Cornell University Oxidationsresistente aat-gentherapie
SE1750774A1 (en) 2017-06-19 2018-12-11 Hepgene Medical Ab Novel nucleic acid molecules and their use in therapy
EP3723790B1 (de) 2017-12-12 2024-03-13 Kamada Ltd Verfahren zur induzierung der immuntoleranz und zur verminderung der antiinflammatorischen antikörperreaktion
US11998654B2 (en) 2018-07-12 2024-06-04 Bard Shannon Limited Securing implants and medical devices
EP4430069A1 (de) 2021-11-09 2024-09-18 Danmarks Tekniske Universitet Varianten von alpha-1-antitrypsin

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4351901A (en) * 1980-03-24 1982-09-28 Cetus Corporation Method for single nucleotide alteration
CA1303530C (en) * 1983-01-21 1992-06-16 Michael Courtney EXPRESSION VECTORS AND THEIR USE FOR THE PREPARATION OF A PROTEIN HAVING HUMAN .alpha. -ANTITRYPSIN ACTIVITY
JPS60186290A (ja) * 1983-08-10 1985-09-21 チモ−ジエネテイツクス　インコ−ポレ−テツド アルフア−１−アンチトリプシンを細菌に表現させる方法
AU3145184A (en) * 1983-08-16 1985-02-21 Zymogenetics Inc. High expression of foreign genes in schizosaccharomyces pombe
ZA8410063B (en) * 1984-01-30 1985-10-30 Smith Kline Rit Expression of human alpha-1-antitrypsin in yeast
DE3585969D1 (de) * 1984-06-14 1992-06-11 Chiron Corp Protease-inhibitoren des alpha-1-antitrypsin typs mit modifizierter aktiever stelle und deren herstellung.
EP0169114B1 (de) * 1984-06-19 1991-01-16 Transgene S.A. Derivate des menschlichen alpha-1-Antitrypins und Verfahren zu deren Herstellung

Also Published As

Publication number Publication date
EP0155188A2 (de) 1985-09-18
EP0155188B1 (de) 1993-12-29
JP2539781B2 (ja) 1996-10-02
JP2750257B2 (ja) 1998-05-13
JPH10113193A (ja) 1998-05-06
DE3587703D1 (de) 1994-02-10
JPH06105689A (ja) 1994-04-19
AU3981985A (en) 1985-09-19
CA1341219C (en) 2001-05-01
EP0566158A1 (de) 1993-10-20
AU593766B2 (en) 1990-02-22
JPS6112289A (ja) 1986-01-20
EP0155188A3 (en) 1986-08-13
US4711848A (en) 1987-12-08

Similar Documents

Publication Publication Date Title
DE3587703D1 (de) Alpha-1-Antitrypsinmutante und dafür kodierende DNS und Herstellung derselben, und solche Mutante verwendende therapeutische Zusammensetzungen und ihre Herstellung.
CA2000786A1 (en) 3-piperidinyl-1,2-benzisoxazoles
CA2026915A1 (en) Stem cell factor
DK0732935T3 (da) Lyofiliserede stamcellefaktorformuleringer
IL110781A0 (en) Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
DE3582274D1 (de) Menschliche monoklonale antikoerper gegen serotypische lipopolysaccharidische determinanten von gram-negativen bakterien und ihre produktion.
ATE84224T1 (de) Desinfektionsverfahren sowie zusammensetzung dafuer.
MY106280A (en) Novel benzopyrido piperidine, piperidylidene and piperazine compounds, compositions, methods of manufacture and methods of use.
ATE40365T1 (de) 3-acylaminomethylimidazo (1,2-a> pyridine, dessen herstellung und therapeutische anwendung.
DE3882593D1 (de) Polypeptid und dessen herstellung.
IT8323205A0 (it) Composizioni farmaceutiche adattivita' antiinfiammatoria e/o analgesica, non ulcerogene.
BG103096A (en) Thrombin inhibitors
DE3578304D1 (de) Pyridazinonderivate, deren herstellung und insektizidische, acaricidische, nematicidische, fungizidische zusammensetzungen.
DE3582895D1 (de) Peptid, dessen herstellung und benutzung.
FI881892A7 (fi) Menetelmä uusien, terapeuttisesti käyttökelpoisten 1,2,5,6-tetrahydropyridiinijohdannaisten valmistamiseksi
DE3577707D1 (de) 3-pyrazolo(1,5-a)pyridinium-cephemverbindungen, deren herstellung und verwendung.
DE69321687D1 (de) Durchlässige materialkomposition, durchlässiges material und dessen herstellung
EP0164719A3 (en) Active site modified protease alpha-1-antitrypsin inhibitors and their production
DE3585097D1 (de) Herstellung menschlicher urokinase.
IT8424266A0 (it) Composizioni farmaceutiche e loro uso come midriatici.
ZA858315B (en) 5-cyanopyridine-2-diazohydroxide,basic salts and methods for production and use
AU578125B2 (en) Pyrazine diazohydroxide compounds
IT8420755A0 (it) Immino-imidazolidine sostituite, dotate di particolari proprieta'terapeutiche loro processo disintesi e composizioni farmaceutiche.
FI931938A7 (fi) Välituotteita 4,5-difluoriantraniliinihapon valmistuksessa
WO1999005264A3 (de) Herstellung humaner mutierter proteine in humanen zellen mittels homologer rekombination

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties